Inhibition of silent information regulator 1 induces glucose metabolism disorders of hepatocytes and enhances hepatitis C virus replication

Hepatology International

Volumn 7, Issue 2, 2013, Pages 524-532

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Zhao, Yong Hua ^a   Kang, Peng ^a   Yan, Bing Zhu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic glucose metabolism; Hepatitis C viruses; Silent information regulator 1 (SIRT1)

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; FORKHEAD BOX O1; FORKHEAD TRANSCRIPTION FACTOR; GLUCOKINASE; GLUCOSE 6 PHOSPHATASE; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NONSTRUCTURAL PROTEIN 5A; PHOSPHO AKT PROTEIN; PHOSPHO FORKHEAD BOX O1; PHOSPHO INSULIN RECEPTOR SUBSTRATE 1; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SILENT INFORMATION REGULATOR 1 PROTEIN; SILENT INFORMATION REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; ENZYME PHOSPHORYLATION; GENE; GLUCOKINASE GENE; GLUCONEOGENESIS; GLUCOSE 6 PHOSPHATASE GENE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEPATITIS C VIRUS; INTRACELLULAR SIGNALING; LIVER CELL; METABOLIC DISORDER; NONHUMAN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 84879838886     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-013-9420-9     Document Type: Article

References (18)

1. Jian Wu Y, Shu Chen L, Gui Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int. 2006;26:166-172
2. Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. Int J Infect Dis. 2012;16:e436-e441
3. Wang T, Campbell RV, Yi MK, Lemon SM, Weinman SA. Role of hepatitis C virus core protein in viral-induced mitochondrial dysfunction. J Viral Hepat. 2010;17:784-793
4. Miyamoto H, Moriishi K, Moriya K, Murata S, Tanaka K, Suzuki T, et al. Involvement of the PA28 gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol. 2007;81:1727-1735
5. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712-716
6. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009;29:1363-1374
7. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, et al. SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci USA. 2009;106:11288-11293
8. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 2005;13:159-163
9. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, et al. SIRT 1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med. 2005;16:237-423
10. Sauve AA, Schramm VL. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry. 2003;42:9249-9256
11. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423:550-555
12. Nakashima K, Takeuchi K, Chihara K, Hotta H, Sada K. Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and independent pathways. Microbiol Immunol. 2011;55:774-782
13. Bujanda L, García-Barcina M, Gutiérrez-de Juan V, Bidaurrazaga J, de Luco MF, de Gutiérrez-Stampa M, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol. 2006;6:35
14. Sener G, Toklu HZ, Sehirli AO, Velioǧlu-Oǧünç A, Cetinel S, Gedik N. Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol Res. 2006;35:62-68
15. Ahn J, Cho I, Kim S, Kwon D, Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol. 2008;49:1019-1028
16. Jiang L, Gu Y, Ye J, Liu F, Zhao Y, Wang C, et al. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. Biotechnol Lett. 2012;34:2205-2212
17. Docherty JJ, Sweet TJ, Bailey E, Faith SA, Booth T. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res. 2006;72:171-177
18. Evers DL, Wang X, Huong SM, Huang DY, Huang ES. 3,4′,5-Trihydroxy- trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res. 2004;63:85-95